한글목차

HER2 억제제 시장은 2023-20281년간 110억 6,653만 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 9.94%를 나타낼 것으로 예측됩니다.

HER2 억제제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 유방암·위암 높은 유병률, 연구개발 진보, 유방암에 대한 의식 고양이 시장 성장을 가속하고 있습니다.

환자 지원 프로그램이 향후 몇 년간 HER2 억제제 시장 성장을 가속하는 주요인 중 하나입니다. 새로운 유방암 진단약의 등장이나 전략적 제휴는 시장의 큰 수요로 연결될 것입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2023년)
• 시장 전망(2023-2028년)

제4장 시장 규모 실적

• 세계의 HER2 억제제 시장(2018-2022년)
• 제품별 부문 분석(2018-2022년)
• 유통 채널별 부문 분석(2018-2022년)
• 지역별 부문 분석(2018-2022년)
• 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• 단일요법 : 시장 규모와 예측(2023-2028년)
• 병용요법 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 제품별

제7장 시장 세분화 : 유통 채널별

• 시장 부문
• 비교 : 유통 채널별
• 소매 약국 : 시장 규모와 예측(2023-2028년)
• 병원 약국 : 시장 규모와 예측(2023-2028년)
• 온라인 약국 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 유통 채널별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측(2023-2028년)
• 유럽 : 시장 규모와 예측(2023-2028년)
• 아시아 : 시장 규모와 예측(2023-2028년)
• 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
• 미국 : 시장 규모와 예측(2023-2028년)
• 독일 : 시장 규모와 예측(2023-2028년)
• 영국 : 시장 규모와 예측(2023-2028년)
• 중국 : 시장 규모와 예측(2023-2028년)
• 캐나다 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 지역별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Amgen Inc.
• AstraZeneca Plc
• Biocon Ltd.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Celltrion Healthcare Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Intas Pharmaceuticals Ltd.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Puma Biotechnology Inc.
• Viatris Inc.

제13장 부록

영문목차

The HER2 (human epidermal growth factor receptor 2) inhibitors market is forecasted to grow by USD 11066.53 mn during 2023-2028, accelerating at a CAGR of 9.94% during the forecast period. The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of breast cancer and gastric cancer, advancements in R&D, and growing awareness about breast cancer.

Technavio's HER2 (human epidermal growth factor receptor 2) inhibitors market is segmented as below:

By Product

• Monotherapy
• Combination therapy

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the patient assistance programs as one of the prime reasons driving the HER2 (human epidermal growth factor receptor 2) inhibitors market growth during the next few years. Also, introduction of new diagnostics for breast cancer and strategic alliances will lead to sizable demand in the market.

The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market covers the following areas:

• HER2 (human epidermal growth factor receptor 2) inhibitors market sizing
• HER2 (human epidermal growth factor receptor 2) inhibitors market forecast
• HER2 (human epidermal growth factor receptor 2) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 (human epidermal growth factor receptor 2) inhibitors market vendors that include Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Samsung Biologics Co. Ltd., Shanghai Henlius Biotech Inc., Viatris Inc., and Celltrion Healthcare Co. Ltd.. Also, the HER2 (human epidermal growth factor receptor 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global HER2 (human epidermal growth factor receptor 2) inhibitors market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global her2 (human epidermal growth factor receptor 2) inhibitors market 2018 - 2022 ($ million)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.3 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Monotherapy - Market size and forecast 2023-2028
• Exhibit 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
• 6.4 Combination therapy - Market size and forecast 2023-2028
• Exhibit 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Product
• Exhibit 42: Market opportunity by Product ($ million)
• Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 46: Chart on Comparison by Distribution Channel
• Exhibit 47: Data Table on Comparison by Distribution Channel
• 7.3 Retail pharmacies - Market size and forecast 2023-2028
• Exhibit 48: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 49: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 50: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• 7.4 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 Canada - Market size and forecast 2023-2028
• Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Amgen Inc.
• Exhibit 111: Amgen Inc. - Overview
• Exhibit 112: Amgen Inc. - Product / Service
• Exhibit 113: Amgen Inc. - Key offerings
• 12.4 AstraZeneca Plc
• Exhibit 114: AstraZeneca Plc - Overview
• Exhibit 115: AstraZeneca Plc - Product / Service
• Exhibit 116: AstraZeneca Plc - Key news
• Exhibit 117: AstraZeneca Plc - Key offerings
• 12.5 Biocon Ltd.
• Exhibit 118: Biocon Ltd. - Overview
• Exhibit 119: Biocon Ltd. - Business segments
• Exhibit 120: Biocon Ltd. - Key offerings
• Exhibit 121: Biocon Ltd. - Segment focus
• 12.6 Boehringer Ingelheim International GmbH
• Exhibit 122: Boehringer Ingelheim International GmbH - Overview
• Exhibit 123: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 124: Boehringer Ingelheim International GmbH - Key news
• Exhibit 125: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 126: Boehringer Ingelheim International GmbH - Segment focus
• 12.7 Bristol Myers Squibb Co.
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key news
• Exhibit 130: Bristol Myers Squibb Co. - Key offerings
• 12.8 Celltrion Healthcare Co. Ltd.
• Exhibit 131: Celltrion Healthcare Co. Ltd. - Overview
• Exhibit 132: Celltrion Healthcare Co. Ltd. - Product / Service
• Exhibit 133: Celltrion Healthcare Co. Ltd. - Key offerings
• 12.9 Dr Reddys Laboratories Ltd.
• Exhibit 134: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 135: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 136: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 137: Dr Reddys Laboratories Ltd. - Segment focus
• 12.10 Eli Lilly and Co.
• Exhibit 138: Eli Lilly and Co. - Overview
• Exhibit 139: Eli Lilly and Co. - Product / Service
• Exhibit 140: Eli Lilly and Co. - Key news
• Exhibit 141: Eli Lilly and Co. - Key offerings
• 12.11 F. Hoffmann La Roche Ltd.
• Exhibit 142: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 144: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus
• 12.12 Intas Pharmaceuticals Ltd.
• Exhibit 147: Intas Pharmaceuticals Ltd. - Overview
• Exhibit 148: Intas Pharmaceuticals Ltd. - Product / Service
• Exhibit 149: Intas Pharmaceuticals Ltd. - Key offerings
• 12.13 Merck KGaA
• Exhibit 150: Merck KGaA - Overview
• Exhibit 151: Merck KGaA - Business segments
• Exhibit 152: Merck KGaA - Key news
• Exhibit 153: Merck KGaA - Key offerings
• Exhibit 154: Merck KGaA - Segment focus
• 12.14 Novartis AG
• Exhibit 155: Novartis AG - Overview
• Exhibit 156: Novartis AG - Business segments
• Exhibit 157: Novartis AG - Key offerings
• Exhibit 158: Novartis AG - Segment focus
• 12.15 Pfizer Inc.
• Exhibit 159: Pfizer Inc. - Overview
• Exhibit 160: Pfizer Inc. - Product / Service
• Exhibit 161: Pfizer Inc. - Key news
• Exhibit 162: Pfizer Inc. - Key offerings
• 12.16 Puma Biotechnology Inc.
• Exhibit 163: Puma Biotechnology Inc. - Overview
• Exhibit 164: Puma Biotechnology Inc. - Product / Service
• Exhibit 165: Puma Biotechnology Inc. - Key offerings
• 12.17 Viatris Inc.
• Exhibit 166: Viatris Inc. - Overview
• Exhibit 167: Viatris Inc. - Business segments
• Exhibit 168: Viatris Inc. - Key news
• Exhibit 169: Viatris Inc. - Key offerings
• Exhibit 170: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 171: Inclusions checklist
• Exhibit 172: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 173: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 174: Research methodology
• Exhibit 175: Validation techniques employed for market sizing
• Exhibit 176: Information sources
• 13.5 List of abbreviations
• Exhibit 177: List of abbreviations